Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis.

• Prif Awduron: John K Thuita (Awdur), Kristina K Wolf (Awdur), Grace A Murilla (Awdur), Qiang Liu (Awdur), James N Mutuku (Awdur), Yao Chen (Awdur), Arlene S Bridges (Awdur), Raymond E Mdachi (Awdur), Mohamed A Ismail (Awdur), Shelley Ching (Awdur), David W Boykin (Awdur), James Edwin Hall (Awdur), Richard R Tidwell (Awdur), Mary F Paine (Awdur), Reto Brun (Awdur), Michael Zhuo Wang (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Public Library of Science (PLoS), 2013-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consor...